About- Taichu Group

About us

Chongde Seeks Truth and Achieves Customers

Company Profile

A Fully Integrated CRO+CDMO Serving Clients Worldwide

Taichu Group is a biotechnology enterprise distinguished by its core competitive advantage in "CRO+CDMO integrated services", specializing in providing end-to-end technical solutions for global innovative drug development spanning from early-stage discovery through preclinical research. Headquartered at Life Bay Park in Shanghai's Lingang Special Area, the Group operates through four wholly owned subsidiaries - Taichu Bio, Tarlead Biologics, TJR Bio, and Taichu (Shenzhen) and a JV company AceMab Ltd - establishing a comprehensive service ecosystem.

Guided by its corporate philosophy of "Advocate of Ethics and Integrity, Quest for Verity" , Taichu Group is committed to streamlining R&D workflows and accelerating therapeutic advancement for global partners. The organization's synergistic service model bridges critical gaps between discovery and commercialization, reinforcing its position as a strategic enabler in the biopharmaceutical innovation value chain.

Corporate culture

Philosophy

Mission, Vision, Values

Philosophy

Mission: Accelerating new drug availability to benefit patients and safeguard health.

Vision: Building fertile ground for future-leading pharmaceutical innovation, empowering medical dreams to become reality.

Values: Advocate of Ethics and Integrity, Quest for Verity.

01
Enterprise Spirit

Excellence Driven, Collaborative Spirit, Service & Dedication, People First

Enterprise Spirit

Excellence Driven:Quality is fundamental to our existence and drives sustainable profitability.

Collaborative Spirit:We champion teamwork and foster win-win partnerships across the organization.

Service & Dedication:We dedicate ourselves to service by aligning individual contributions with shared success.

People First:Empowering our people through respect, motivation, and development.

02

Team

Jing Ma Ph.D.

Chairman and CSO of Taichu Group

Jing Ma Ph.D.

Chairman and CSO of Taichu Group

Ph.D. in Drug Toxicology; Doctoral Supervisors of China National Pharmaceutical Industry Research Institute, Fudan University and Shanghai Jiao Tong University

General Manager and Professor of Shanghai National Center for New Drug Safety Evaluation & Research (2006-2016); Founder and Chairman of the Board of Shanghai Innostar Biotechnology Co., Ltd, (2010-2019)

Expert in New Drug Review and GLP Inspection, National Medical Products Administration (NMPA); Member, ICH Working Group; Vice President, Chinese Society of Toxicology; Honorary Chair, Toxicology Specialty Committee, Chinese Pharmacological Society

Successfully passed three OECD GLP certifications and two FDA GLP inspections;

Publication of more than 150 article;

Established 51 new methods for drug toxicology research; more than 7,000 toxicological studies; >3,000 new drugs developed for companies in China and overseas; 34 first-class new molecules were approved for marketing; >100 new drugs were approved for clinical trials in the United States and other countries;

Participated in drafting/revising the GLP inspection standard in NMPA and 15 CDE safety guideline.

11 years of pharmacology experience and 29 years of combined pharmacology/toxicology teaching and research expertise; 18 years of GLP/CRO management experience in the pharmaceutical R&D sector.
Xun Liu Ph.D.

CEO of Taichu Group

Xun Liu Ph.D.

CEO of Taichu Group

Ph.D. from Rutgers University, USA;

Postdoctoral fellow at MIT. Studied under Nobel Prize Laureate Professor Gobind Khorana and completed three and a half years of postdoctoral research;

More than 30 years of experience in pharmaceutical industry;

Principal Engineer of Bayer Pharmaceuticals and Production Specialist for Bayer top-selling drug Kogenate®;

Tenured Research Scientist at Vaccine Research Center (National Institutes of Health)，responsible for process development, clinical and commercial manufacturing of therapeutic and prophylactic vaccines;

Vice President of Jiangsu Hengrui Pharmaceutical Co., Ltd. and President of Hengrui Pharmaceutical Biomedical Development Division since 2015. Commercial development of more than 50 new drugs, of which 27 had entered clinical trials and 5 products had been approved for marketing;

Chief Technical Officer of Overland Pharma;

Senior Advisor of Hillhouse Investment.
Jianliang Li Ph.D.

General Manager of AceMab

Jianliang Li Ph.D.

General Manager of AceMab

Graduated from the School of Life Sciences at Fudan University with a PhD in Embryonic Stem Cell Biology from Sheffield University;

Former senior scientist and project leader at GE Healthcare;

Former team leader and senior scientist in the biopharmaceutical new drug development department of AstraZeneca (UK);

Over 20 years of experience in cancer research, stem cell biology, and molecular biology research and development management;

The first inventor of a patent and the second inventor of a patent.
Jason Zhou Ph.D.

Senior Vice President of TJR Bio

Jason Zhou Ph.D.

Senior Vice President of TJR Bio

Ph.D. in Organic Chemistry from the University of South Florida, USA. Completed postdoctoral research at Texas A&M University under the mentorship of Prof. James Sacchettini.

Served as CMC Senior Director at Visirna, responsible for CMC activities of siRNA therapeutics including IND/NDA regulatory submissions for imported products, localized technical transfers, CMC development/scale-up of in-house pipelines, and clinical supply chain operations. Accumulatively completed 7 siRNA drug INDs, China’s first biotech-led siRNA pre-NDA/NDA submissions, and demonstrated in-depth understanding of FDA and NMPA pharmaceutical regulatory requirements and CMC/NDA study frameworks for oligonucleotide drugs.

Previously engaged in drug discovery at GSK US Pharmaceuticals, covering medicinal chemistry design and synthesis.

Led the Early-Stage Process R&D Department at STA Pharma (WuXi), directing teams to complete early-phase CMC process development for ~70 small molecule drugs.

Held CMC leadership roles at InnoCare Pharma and AnHeart, overseeing end-to-end CMC. Contributed to 18+ small molecule IND filings, 2 PPQ campaigns, and 1 approved NDA.

Accumulated 20+ years of experience in small molecule & siRNA innovative drugs across CMC development, CMC strategy and global regulatory filing.
Zhiyong Lin

Vice President of Tarlead

Zhiyong Lin

Vice President of Tarlead

With 20 years of dedicated experience in the biopharmaceutical field, previously served as Head of Downstream Process Development at Innovent Biologics; Director of Drug Substance Manufacturing for Early-Phase Clinical and Commercial Production at Innovent Biologics; Vice President of Process Development at AusciGen Biologics; Vice President & Head of Group R&D Center at AusciGen Biologics.

Senior expert in biologics CMC, possessing in-depth understanding of CMC regulatory requirements and mastery of full lifecycle processes including process development, scale-up, technology transfer, and commercial manufacturing for biological macromolecules/drugs. Accumulated extensive CMC development experience through leading 50+ projects, with 2 novel drugs and 4 biosimilars successfully approved for marketing and post-approval changes implemented; one biosimilar has passed Pre-Approval Inspection (PAI) and is currently under CDE review for market authorization.

Extensive experience leading construction of compliant laboratories and GMP drug substance production facilities, including successful establishment of: 2 R&D center laboratories; 1 GMP drug substance facility for early-phase clinical production (500L scale); 1 commercial-scale stainless-steel drug substance production facility (36,000L scale). Proven capability in standardizing biopharmaceutical process systems and ensuring robust production compliance.
Zhihua Zhang Ph.D.

Senior Toxicology Consultant

Zhihua Zhang Ph.D.

Senior Toxicology Consultant

Ph.D., Toxicology, Rutgers University/University of Medicine and Dentistry of New Jersey, Piscataway, NJ

As President, Ridge Pharma Consulting, LLC, NJ

Former Executive Vice President, Early Development and Project Management in Ark Biosciences, Inc., Shanghai

More than twenty-six years’ experience in pharmaceutical/biotech industry R&D strategic planning and execution

An expert intoxicology, pharmacology/animal efficacy models, DMPK / ADME, and early clinical development

Successful filings of more than thirty (25) INDs and five (5) NDAs in the US, four (4) MAAs in Europe, and multiple INDs in China and Australia

Served as the first president of American Association of Chinese in Toxicology and a board-certified toxicologist.

Group structure

Antibody Discovery and Design

Taichu Biotechnology

Pre-Clinical Research

Tarlead Biologics

Biologics Development and Manufacturing

Nucleic Acid Drug Process Development and GMP Manufacturing

Taichu (Shenzhen)

Comprehensive Innovative Therapeutic Development Advisory Services

Investor Relations

As of March 2025, Taichu Biotechnology has completed the B-round financing.

This round of financing is led by TAILONG VC and recognized by well-known investment institutions in the industry.

Tel021-80403636

E-mailmarketing@taichubio.com

AddressNo. 308 Pingda Road, Lingang Special Area,Shanghai, China

AceMab Wechat official account

Taichu Biotechnology Wechat official account

Tarlead Wechat official account

TJR BIO Wechat official account

Taichu (Shenzhen) Wechat official account

Copyright ©2023 Taichu Group. All Rights Reserved沪ICP备2023012905号-1

Legal Notice丨 Website Map丨

Links

Baidu